-$0.06 Earnings Per Share Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter
Brokerages predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report earnings of ($0.06) per share for the current quarter, Zacks reports. Five analysts have made estimates for BioDelivery Sciences International’s earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.01). BioDelivery Sciences International reported earnings per share of ($0.16) during the same quarter last year, which suggests a positive year over year growth rate of 62.5%. The company is expected to issue its next earnings report on Thursday, August 8th.
On average, analysts expect that BioDelivery Sciences International will report full-year earnings of ($0.14) per share for the current financial year, with EPS estimates ranging from ($0.42) to ($0.05). For the next fiscal year, analysts forecast that the firm will report earnings of $0.25 per share, with EPS estimates ranging from $0.09 to $0.46. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. The business had revenue of $19.77 million for the quarter, compared to the consensus estimate of $19.60 million. BioDelivery Sciences International had a negative net margin of 42.09% and a negative return on equity of 43.40%.
NASDAQ BDSI traded up $0.10 on Tuesday, hitting $4.34. 533,409 shares of the company were exchanged, compared to its average volume of 955,196. The company has a market cap of $370.65 million, a price-to-earnings ratio of -5.95 and a beta of 0.41. The company has a quick ratio of 2.57, a current ratio of 2.88 and a debt-to-equity ratio of 1.90. BioDelivery Sciences International has a 1-year low of $2.31 and a 1-year high of $5.37.
In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 9,050 shares of the company’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $5.20, for a total transaction of $47,060.00. Following the transaction, the director now directly owns 2,509,005 shares in the company, valued at approximately $13,046,826. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Healthcare Master Fun Broadfin sold 1,800,000 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $5.00, for a total transaction of $9,000,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,855,335 shares of company stock worth $19,280,285. Corporate insiders own 13.26% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in BDSI. Nantahala Capital Management LLC raised its position in shares of BioDelivery Sciences International by 64.0% in the 4th quarter. Nantahala Capital Management LLC now owns 2,733,567 shares of the specialty pharmaceutical company’s stock valued at $10,114,000 after acquiring an additional 1,066,900 shares during the period. Vanguard Group Inc raised its position in shares of BioDelivery Sciences International by 0.3% in the 3rd quarter. Vanguard Group Inc now owns 2,380,456 shares of the specialty pharmaceutical company’s stock valued at $6,666,000 after acquiring an additional 7,600 shares during the period. Rubric Capital Management LP raised its position in shares of BioDelivery Sciences International by 14.8% in the 1st quarter. Rubric Capital Management LP now owns 2,292,132 shares of the specialty pharmaceutical company’s stock valued at $12,148,000 after acquiring an additional 296,173 shares during the period. Morgan Stanley raised its position in shares of BioDelivery Sciences International by 6,392.8% in the 1st quarter. Morgan Stanley now owns 1,748,052 shares of the specialty pharmaceutical company’s stock valued at $9,264,000 after acquiring an additional 1,721,129 shares during the period. Finally, Emerald Advisers LLC raised its position in shares of BioDelivery Sciences International by 881.4% in the 1st quarter. Emerald Advisers LLC now owns 1,734,422 shares of the specialty pharmaceutical company’s stock valued at $9,192,000 after acquiring an additional 1,557,692 shares during the period. Institutional investors own 58.26% of the company’s stock.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Featured Story: Real Estate Investment Trust (REIT) ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.